The study is a post-marketing performance and safety study, designed as a comparative, prospective, multicenter, simple-blind, randomized clinical trial. 300 subjects requiring a primary or a secondary root canal treatment will be enrolled in 2 groups (150 in each group). The aim of the study is to demonstrate the superiority of the hydrocortisone-containing root canal sealer Endomethasone N RCS, compared to the hydrocortisone-free root canal sealer Endomethasone SP RCS, with regard to reduction of the maximum post-operative spontaneous pain during the 7 days following the root canal treatment.

Root canal treatment procedures will be in accordance with the allocation by randomisation of Endomethasone N RCS or Endomethasone SP RCS. The spontaneous and the Masticatory pain will be record at predefined times, a phone call will be done at 48h and a visit will be realized at day 7 (max Day 14).

Inclusion Criteria:

• Adult male or female (age ≥ 18 years);
• Patient requiring root canal treatment or retreatment;
• Patient who will need a single visit for the root canal therapy, for a mature molar or second premolar, with or without pre-operative pain
• Patient who received information and gave written consent (signed informed consent form);
• Subject affiliated to a health insurance system, or is a beneficiary (art. L.1121-11, Code of Public Health, France).

Exclusion Criteria:

• Pulpotomy or pulpectomy performed at a prior visit;
• Tooth with apical calcification (sealer unable to reach the root apex);
• Tooth with suspected root perforation;
• Immature tooth (too wide root apex requiring an apexification);
• Other dental treatment ongoing or scheduled within the study period;
• At least one symptomatic tooth among those that are not included in this study
• Known hypersensitivity to steroids, local anesthetics, or any component of study medical devices;
• Subject using long term anti-inflammatory drugs;
• Use of illicit substances during the 48h before the first visit (cannabis, cocaine…);
• Presence of any significant medical finding or significant history such as uncontrolled systemic diseases that may impact the safety, the interpretation of the results and/or the participation of the subject in the study according to the opinion of the investigator;
• Subject who cannot be contacted in case of emergency (phone number);
• Simultaneous participation in another clinical trial or subject still within the exclusion period of a previous clinical trial;
• Vulnerable subjects (art. L.1121-5 and L.1122-1-2, Code of Public Health, France; art. 66 of the Regulation (EU) 2017/745 on medical devices)

The color of the two powders are not the same. The dentist will not be blinded to the treatment, but the patient will. The study is simple-blinded.